MarketPulse

melanoma

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Iovance's Personalized Cancer Therapy Targets 60%+ Growth, But Execution Risk Looms

Iovance shows 60.6% fiscal 2025 revenue growth for its personalized cancer therapy Amtagvi, but faces manufacturing complexity and profitability challenges ahead.
IOVAFDA approvalbiotech
The Motley FoolThe Motley Fool··Adria Cimino

Iovance Biotherapeutics Expands Market Presence Following Amtagvi Approval

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.
IOVAbiotechclinical trials